Lakhani Saquib A, Bogue Clifford W
Section of Pediatric Critical Care, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Curr Opin Pediatr. 2003 Jun;15(3):278-82. doi: 10.1097/00008480-200306000-00009.
Despite extensive research, bacterial sepsis and its associated systemic inflammation remain a major cause of morbidity and mortality in the pediatric intensive care unit. Advances in molecular biology, however, have improved our understanding of this disease process and have opened up new avenues of potential therapeutic approaches. One such exciting area has been the substantial and still growing evidence that the mammalian immune system uses a family of Toll-like receptors (TLRs) to generate a response to molecular patterns present on invading microorganisms. In particular, TLR4 is part of a recognition complex for bacterial lipopolysaccharide (LPS), thus raising the likelihood of its involvement in the inflammatory response to bacterial sepsis. This review highlights our understanding of the molecular biology of these receptors, focusing on the LPS response, and concluding with a summary of ongoing evaluation and potential therapeutic strategies for treating sepsis through blockade of TLR signaling.
尽管进行了广泛的研究,但细菌性败血症及其相关的全身炎症仍然是儿科重症监护病房发病和死亡的主要原因。然而,分子生物学的进展增进了我们对这一疾病过程的理解,并开辟了潜在治疗方法的新途径。一个令人兴奋的领域是,有大量且仍在不断增加的证据表明,哺乳动物免疫系统利用一类Toll样受体(TLR)对入侵微生物上存在的分子模式产生反应。特别是,TLR4是细菌脂多糖(LPS)识别复合物的一部分,因此增加了其参与对细菌性败血症炎症反应的可能性。本综述重点介绍了我们对这些受体分子生物学的理解,着重于LPS反应,并最后总结了通过阻断TLR信号传导治疗败血症的正在进行的评估和潜在治疗策略。